NasdaqGM - Nasdaq Real Time Price USD

Neuronetics, Inc. (STIM)

2.4300 -0.2750 (-10.17%)

At close: November 5 at 4:00:01 PM EST

2.3910 -0.0390 (-1.60%)

After hours: 7:08:10 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 1d ago

STIM
-11.61%
Neuronetics Reports Third Quarter 2026 Financial and Operating Results

GlobeNewswire 1d ago

STIM
-11.61%
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

GlobeNewswire 15d ago

STIM
-11.61%
Neuronetics Reports Second Quarter 2026 Financial and Operating Results

GlobeNewswire 2mo ago

STIM
-11.61%
Neuronetics and Jorey Chernett Announce Shared Vision

GlobeNewswire 3mo ago
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

GlobeNewswire 3mo ago

STIM
-11.61%
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

GlobeNewswire 3mo ago

STIM
-11.61%
AXGN
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

GlobeNewswire 3mo ago

STIM
-11.61%
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

GlobeNewswire 5mo ago

STIM
-11.61%
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

GlobeNewswire 6mo ago

STIM
-11.61%
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

GlobeNewswire 6mo ago

STIM
-11.61%
Neuronetics Comments on Letter from Pointillist Family Office

GlobeNewswire 6mo ago

STIM
-11.61%

Performance Overview

Return	STIM	S&P 500 (^GSPC)
YTD	+76.09%	+7.42%
1-Year	-11.31%	+8.20%
3-Year	+73.57%	+68.73%

U.S. markets closed

Neuronetics, Inc. (STIM)

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Neuronetics and Jorey Chernett Announce Shared Vision

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

Neuronetics Comments on Letter from Pointillist Family Office